Summary:
The purpose of this study was to identify risk factors for hypothyroidism after bone marrow transplantation (BMT) for high-risk or relapsed acute lymphoblastic leukaemia (ALL) in children. In all, 388 children with acute lymphoblastic leukaemia underwent allogeneic bone marrow transplantation between 1984 and 1994. Overall 5-year survival was 54.6%. Thyroid function was assessed in the 153 patients with more than 5 years of follow-up. In total, 16 patients developed uncompensated hypothyroidism (UH) and 46 compensated hypothyroidism (CH) a median of 2.9 and 2.7 years, respectively, after BMT. Thyroid dysfunction-free survival rates were 73.2% after 5 years and 59.2% after 10 years. Three factors were significantly associated with the onset of hypothyroidism, namely age, bone marrow transplantation in second remission, and single-dose total body irradiation (TBI). Ultrasonography of the thyroid showed nodules in 10 of 35 patients. The median time from BMT to nodule detection was 7.8 years. Cytology (n=5) and surgery (n=4) showed no evidence of thyroid cancer. Four of the 14 patients who received cytoreduction without TBI but with busulphan and cyclophosphamide developed UH (n=2) or CH (n=2). We concluded that children who undergo BMT for ALL are at a high risk of subsequent thyroid dysfunction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Collet D . Modelling Survival Data in Medical Research. Chapman & Hall: London, 1994.
Schemper M, Stare J . Explained variation in survival analysis. Stat Med 1996; 19: 1999–2012.
Pasqualini T, McCalla J, Berg S et al. Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukaemia. Acta Endocrinol (Copenh) 1991; 124: 375–380.
Boulad F, Bromley M, Black P et al. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant 1995; 15: 71–76.
Borgström B, Bolme P . Thyroid function in children after allogenic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 59–64.
Thomas BC, Stanhope R, Plowman PN et al. Endocrine function following single fraction and fractionated total body irradiation for bone marrow transplantation in childhood. Acta Endocrinol 1993; 128: 508–512.
Sanders JE, and the long term follow-up team. Endocrine problems in children after bone marrow transplant for hematologic malignancies. Bone Marrow Transplant 1991; 8: 2–4.
Michel G, Socié G, Gebhard F et al. Late effects of allogenic bone marrow transplantation for children with acute myeloblastic leukaemia in first complete remission: the impact of conditioning regimen without total body irradiation, a report from the Société Française de Greffe de Moelle. J Clin Oncol 1997; 15: 335–340.
Katsanis E, Shapiro RS, Robinson LL et al. Thyroid dysfunction following bone marrow transplantation: long term follow-up of 80 pediatric patients. Bone Marrow Transplant 1990; 5: 335–340.
Toubert ME, Socié G, Gluckman E et al. Short and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. Br J Haematol 1997; 98: 453–457.
Thuret I, Michel G, Carla H et al. Long term side-effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia. Bone Marrow Transplant 1995; 15: 337–341.
Cohen A, Rovelli A, Van Lint MT et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant 2001; 28: 1125–1128.
Acknowledgements
This work was supported by grants from CHIRON, AMGEN and Ligue Contre le Cancer de la Loire. We thank all the clinicians who gave us access to their patients' data, namely E Gluckman (Hôpital St Louis, Paris), G Souillet (Hôpital Debrousse, Lyon), JH Bourhis (Institut Gustave Roussy, Villejuif), JP Jouet (CHU, Lille), F Bernaudin (Hôpital Henri Mondor, Creteil) F Mechinaud (Hôtel Dieu, Nantes), A Fischer (Hôpital Necker, Paris) F Demeocq (Hôtel Dieu, Clermont-Ferrand), H Rubie (Hôpital Purpan, Toulouse), D Blaise (Institut Calmette, Marseille), JP Vannier (Hôpital d'enfants, Rouen), P Lutz (CHU, Strasbourg), D Plantaz (CHU, Grenoble), P Boutard (CHU, Caen), G Leverger (Hôpital Trousseau, Paris), V Gandemer (CHU, Rennes), and B Deygas for her technical assistance. We thank David Young for editing this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berger, C., Le-Gallo, B., Donadieu, J. et al. Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant 35, 991–995 (2005). https://doi.org/10.1038/sj.bmt.1704945
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704945
Keywords
This article is cited by
-
Impact of allogeneic stem cell transplantation on thyroid function
Journal of Endocrinological Investigation (2023)
-
A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation
Cancer and Metastasis Reviews (2020)
-
Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters
Bone Marrow Transplantation (2016)